Prothena公司透露,若百时美施贵宝决定推进PRX019项目,其有望获得一笔高达5500万美元的临床里程碑付款。而施贵宝的这项决策,预计将在2026年年底前作出。
Prothena公司透露,若百时美施贵宝决定推进PRX019项目,其有望获得一笔高达5500万美元的临床里程碑付款。而施贵宝的这项决策,预计将在2026年年底前作出。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.